Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
There is a great interest in and demand for SyntheticMR's products in all priority markets. However, a number of purchasing processes with significant order values are delayed at the customer level, which affects the outcome in the quarter. The processes are still ongoing and the experience so far is that the restrictions are temporary and have no long-term impact.
Net sales for the first quarter 2022 are estimated to amount to approximately SEK 10 million (14.7). The figures are preliminary and unaudited. The full interim report for the first quarter will be published on May 10, 2022, as previously announced.
"As communicated earlier, our business sometimes have large fluctuations over the quarters. It is important to point out, however, that the response from the market for our offerings after the previous record quarter is unabated strong. My solid belief in the potential for the current and coming years is intact", says Ulrik Harrysson, CEO, SyntheticMR.
This disclosure contains information that SyntheticMR AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 05-04-2022 18:26 CET.